MedTrace Logo

Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate

NCT04598620 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2022-02-15

No results posted yet for this study

Summary

The main objective of this study is to assess if analysis of exhaled breath condensate (EBC) can provide useful prognostic markers for admission to the intensive care unit (ICU) due to acute respiratory insufficiency among patients with Coronavirus disease 2019 (COVID-19). Additionally, to give a characterization of the lung damage caused by COVID-19 by analysis of daily blood samples.

The hypothesis is that the protein content of the EBC from COVID-19 patients who require admission to the ICU differs from the EBC from COVID-19 patients with uncomplicated hospitalization, potentially providing diagnostic markers of COVID-19 related pulmonary damage.

Conditions

  • Covid19
  • Corona Virus Infection

Sponsors & Collaborators

  • Aarhus University Hospital Skejby

    collaborator OTHER

  • Inger Lise Gade

    lead OTHER

Principal Investigators

  • Inger L Gade, MD, PhD · Aalborg University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-19
Primary Completion
2021-10-01
Completion
2021-10-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04598620 on ClinicalTrials.gov